ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.810
+0.060 (3.43%)
At close: Jul 2, 2026, 4:00 PM EDT
1.840
+0.030 (1.66%)
After-hours: Jul 2, 2026, 7:24 PM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 2.03M EUR in the quarter ending March 31, 2026, a decrease of -57.12%. This brings the company's revenue in the last twelve months to 13.64M, down -30.51% year-over-year. In the year 2025, ProQR Therapeutics had annual revenue of 16.35M, down -16.36%.
Revenue (ttm)
13.64M EUR
Revenue Growth
-30.51%
P/S Ratio
16.24
Revenue / Employee
73,092 EUR
Employees
187
Market Cap
255.43M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Fulcrum Therapeutics | 80.00M |
| Cellectis | 75.11M |
| Invivyd | 55.87M |
| Orchestra BioMed Holdings | 32.72M |
| Sol-Gel Technologies | 18.47M |
| Entrada Therapeutics | 5.74M |
| AC Immune | 4.62M |
PRQR News
- 9 days ago - ProQR Therapeutics price target lowered to $10 from $14 at Raymond James - TheFly
- 9 days ago - ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch - TheFly
- 10 days ago - ProQR Therapeutics price target lowered to $3 from $4 at Chardan - TheFly
- 10 days ago - ProQR Therapeutics Slides: Conference presentation - Filings
- 10 days ago - ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering - TheFly
- 10 days ago - ProQR Therapeutics announces positive Phase 1 data for AX-0810 - TheFly
- 10 days ago - ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 10 days ago - ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform - GlobeNewsWire